← Back to Clinical Trials
Recruiting NCT06885905

Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Chronic Pulmonary Aspergillosis
Sponsor Imperial College London
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-27
Completion 2025-08-23

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Eligibility Criteria

Inclusion Criteria: 1. All patients \>/= 18 years old and able to provide informed consent 2. Patients with a diagnosis of chronic pulmonary aspergillosis 3. To speak and understand English 4. Able to provide informed consent

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE CHRONIC PULMONARY ASPERGILLOSIS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}